Trial Profile
A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Vapendavir (BTA798) on the Pharmacokinetics of Orally Administered Midazolam, a CYP3A4 Substrate, in Healthy Male and Female Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Midazolam (Primary) ; Vapendavir (Primary)
- Indications Rhinovirus infections
- Focus Pharmacokinetics
- Sponsors Biota Inc
- 01 Aug 2014 New trial record